PROBLEM TO BE SOLVED: To provide a polishing fluid composition for glass hard disk substrates which combines a high polish rate and high cleanliness and which, even when used in a fluid-circulating polishing system, can keep a high polish rate for a long time.

Provided is a polishing fluid composition for glass hard disc substrates which combines a high polish rate and high cleanliness and which, even when used in a fluid-circulating polishing system, can keep a high polish rate for a long time. A polishing fluid composition for glass hard disc substrates which comprises an amine compound, an acid, silica particles, and water, wherein the amine compound is selected from the group consisting of amino alcohols, piperazine, and derivatives thereof and co...

Liposomal-encapsulated taxane or an antineoplastic derivative thereof or a mixture thereof is provided which is used to effect a therapeutically enhanced method of treating cancer. The liposomal encapsulated paclitaxel allows for administration to a patient, particularly a human patient, in less than one hour without substantial toxicity.

The present invention relates to the use of staurosporine derivatives for the preparation of a drug for the treatment of FIP1L1-PDGFRalpha-induced myeloproliferative diseases, especially for the curative and/or prophylactic treatment of hypereosinophilic syndrome and hypereosinophilic syndrome with resistance to imatinib, and to a method of treating hypereosinophilic syndrome and hypereosinophilic syndrome with resistance to imatinib, or other diseases associated with FIPL1-PDGFRa or similar mut...

The present invention relates to the use of staurosporine derivatives for th e preparation of a drug for the treatment of FIP1L1-PDGFR.alpha.-induced myeloproliferative diseases, especially for the curative and/or prophylactic treatment of hypereosinophilic syndrome and hypereosinophilic syndrome with resistance to imatinib, and to a method of treating hypereosinophilic syndro me and hypereosinophilic syndrome with resistance to imatinib, or other disease s associated with FIPL1-PDGFRa or simila...

PURPOSE:To obtain a sustained release formulation, by coating a granular composition prepared by coating the surface of small granular nuclei with a diclofenac salt and binder with a specific film and capable of providing a small difference between individuals in a change of elution and blood level of the diclofenac when administered to humans. CONSTITUTION:A composition obtained by coating a granular composition prepared by uniformly coating the surface of small granular nuclei having 0.1-3mm g...